Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ECV-304

Pharmacological Research

Volumn 44, Issue 6, 2001, Pages 513-518

  Deng, Ying ^a   Xu, Huibi ^a   Huang, Kaixun ^a   Yang, Xiangliang ^a   Xie, Changsheng ^a   Wu, Juan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiogenesis; Apoptosis; Endothelial cell; Realgar particles

Indexed keywords

ARSENIC TRIOXIDE; REALGAR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; PARTICLE SIZE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; UMBILICAL VEIN;

EID: 0035660304     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0885     Document Type: Article

References (51)

1. What is the evidence that tumors are angiogenesis dependent?
2. Angiogenesis
3. The role of angiogenesis in tumor growth
4. Review article: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
5. Angiogenesis in cancer, vascular, rheumatoid and other disease
6. Gene therapy strategies for tumor antiangiogenesis
7. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy
8. Arsenic and cancer
9. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts
10. Comparison of arsenic induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture
11. Sister-chromatid exchange (SCE) among individuals chronically exposed to arsenic in drinking water
12. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
13. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
14. AI-LING I treated 32 cases of acute promyelocytic leukemia
15. Clinical study on the treatment of acute promyelocytic leukemia mainly with composite Indigo Naturalis tablets
16. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
17. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
18. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
19. 3 exerts dose-dependent dual effects on APL cells
20. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
21. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
22. Arsenic-induced apoptosis in malignant cells in vitro
23. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide
24. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1
25. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery
26. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity
27. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement
28. Nanoparticles and liposomes: A state of the art
29. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)/poly(epsilon-caprolactone) (PCL) amphiphilic block copolymeric nanospheres. II. Thermoresponsive drug release behaviors
30. Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake?
31. Preparation, characterization and performance evaluation of neomycin-HSA microspheres
32. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent
33. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill
34. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner
35. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: Association with the induction of apoptosis in leukemia HL-60 cells
36. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
37. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR α independent manner
38. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines
39. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3
40. Arsenite induces apoptosis of murine T lymphocytes through membrane raft-linked signaling for activation of c-Jun amino-terminal kinase
41. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
42. 3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on cell lineages
43. Incorporation of polymeric nanoparticles into solid dosage forms
44. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization
45. Nanoparticle DNA carrier with poly(L-lysine) grafted polysaccharide copolymer and poly(D-, L-lactic acid)
46. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics
47. Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size
48. Gastrointestinal uptake of biodegradable microparticles: Effect of particle size
49. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement
50. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug